Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00562952

Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC)

Nt-proBNP Guided Prevention of Cardiovascular Events in a Population of Diabetic Patients Without a History of Cardiac Disease

Sponsor: Medical University of Vienna

Conditions Coronary Artery Disease Diabetes Mellitus Heart Failure

Interventions Telmisartan, Bisoprolol placebo

Updated 5 times since 2017 Last updated: May 2, 2012 Started: Nov 30, 2007 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00562952, this PHASE2/PHASE3 trial focuses on Coronary Artery Disease and Diabetes Mellitus and remains completed. Sponsored by Medical University of Vienna, it has been updated 5 times since 2007, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Medical University of Vienna
Roche Pharma AG

Data source: Medical University of Vienna

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria